Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT01708954 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

125

Enrollment

NIH

Sponsor class

Conditions

Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

DRUG: Cabozantinib S-malate
DRUG: Erlotinib Hydrochloride
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)